Trial NCT01455389

View at ClinicalTrials.gov 
Org. Study IDs: ONC-002

Last trial update was posted on 2022-03-02

MeSH Interventions

Dexamethasone Diphenhydramine Erlotinib Hydrochloride Promethazine

MeSH Conditions

Lung Neoplasms

Other Conditions

Lung Cancer

Stopping Reasons

Trial terminated by sponsor after decision to evaluate combination of quaratusugene ozeplasmid and osimertinib instead of further evaluating quaratusugene ozeplasmid and erlotinib.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID